Skip to main content

Use of Gonadotropin-Releasing Hormone (GnRH) Agonists in Patients with Gender Dysphoria: A Descriptive Analysis

    Basic Details
    Date Posted
    Medical Product
    gonadotropin-releasing hormone agonists
    Health Outcome(s)
    duration of use

    In this report we examined counts and follow-up time for individuals with a diagnosis of gender dysphoria in the Merative™ MarketScan® Research Databases. In addition, we examined counts of individuals using gonadotropin-releasing hormone (GnRH) agonists with or without an inclusion requirement for a diagnosis of gender dysphoria before their GnRH agonist exposure.

    The study period includes data from October 1, 2015 to June 30, 2021. We queried the  Merative™ MarketScan® Research Databases on October 5, 2022.

    Additional Details
    FDA Center
    Time Period
    October 1, 2015 - June 30, 2021
    Analysis Type
    Population / Cohort
    Individuals 12 to 20 years of age
    Data Sources
    Merative™ MarketScan® Research Databases